Please try another search
For the nine months ended 30 September 2019, Spark Therapeutics Inc revenues increased 10% to $56.7M. Net loss increased from $13.6M to $185.2M. Revenues reflect Product sales, net increase of 81% to $28.2M. Higher net loss reflects Other income decrease from $110M (income) to $0K, Research and development increase of 39% to $122.7M (expense), Selling, general and administrative increase of 25% to $116.1M (expense).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 22.45 | 13.5 | 20.77 | 13.16 |
Gross Profit | 17.4 | 12.21 | 17.28 | 11.06 |
Operating Income | -68.66 | -66.44 | -56.85 | -58.38 |
Net Income | -66.6 | -64.23 | -54.36 | -65.26 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 703.5 | 750.25 | 755.51 | 814.35 |
Total Liabilities | 357.49 | 348.65 | 304.48 | 317.84 |
Total Equity | 346.01 | 401.6 | 451.03 | 496.51 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 0 Months |
Cash From Operating Activities | -100.45 | -82.07 | -32.1 | -70.56 |
Cash From Investing Activities | 211.96 | 110.99 | 16.39 | 59.16 |
Cash From Financing Activities | -1.06 | -0.05 | -3.22 | 62.95 |
Net Change in Cash | 110.39 | 28.86 | -18.93 | 51.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review